Skip to main content
OpenTrials
Completed

NCT Number: NCT06520787

DAta-driven personaLIzation of a digitAl Health Solution to Support Family Caregivers of Children With Chronic Conditions

The goal of this feasibility study is to explore the needs of families with children with obesity and evaluate the impact of a combined intervention (children with obesity receiving pharmacological therapy in combination with the Adhera Caring Digital Program®) on treatment satisfaction, adherence, and mood. The main objectives are:

* To evaluate the impact of the treatment combination (ACDP® and pharmacological treatment) in terms of satisfaction, engagement, adherence and mood, in families with children with obesity. * To better understand the educational and support needs of the families of children with obesity while under treatment and lifestyle changes.

Participants will:

* Use the Adhera Caring Digital Program® (ACDP®) for obesity, which includes digital therapeutic software, personalized messages, and educational materials. * Take pharmacological treatment as prescribed for one year. * Wear activity wristbands/watches to collect biometric data. * Attend monthly clinic visits for assessments and monitoring. * Complete psychometric questionnaires to measure satisfaction, adherence, and emotional outcomes. * Engage in chat-based communication and video conferencing with health coaches for support and monitoring.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity, Childhood Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Pediatric Obesity Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitario Miguel Servet

Zaragoza, Aragon, 50009, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caregivers of children between 13 and 18 years who are diagnosed with obesity and undergoing treatment according to the approved label by AEMPS1 (adolescents with obesity aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex).
  • Families of children with obesity who have been under pharmacological treatment before screening. This includes treatment with any of the following medications orlistat, metformin, liraglutide, semaglutide.
  • Participants who are willing to join ACDP® for 10 months and can interact with a smartphone during that time.
  • The family is willing to complement the pharmacological obesity treatment with a digital intervention.
  • Participants (patients and their caregivers) must be willing to use wearables for the entire length of the study.
  • Parents previously using a wearable will agree not to use it during the length of the study, as their wearable account must be synched to the patient's device. Further, they may need to agree on changing the account data for height, weight, and gender in their Google account.

Exclusion criteria

  • Families not fluent in Spanish.
  • Families of children with obesity and comorbidities.
  • Families of children with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine causes).

Treatment and study plan

ACDP® and pharmacological treatment for obesity

Combination Product

40 Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention. After the recruitment, the family will join Adhera Caring Digital Program® for 10 months. The combined intervention (digital and pharmacological intervention) will last one year, and there will be a 2-month follow-up. During the whole study (12 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).

Primary outcomes

  1. Treatment satisfaction

    Time frame: Day 1 to Day 365

    Treatment satisfaction measured by Treatment Expectation Scale/Treatment Satisfacyion Scale. Minimum Value: 0. Maximum Value: 10. Interpretation: Higher scores indicate better outcomes (greater treatment expectation/satisfaction).

  2. Treatment adherence 1

    Time frame: Day 1 to Day 365

    Treatment adherence measured by injection (self-reported). Unit of measure: Number of injections (quantitative data)

  3. Treatment adherence 2

    Time frame: Day 1 to Day 365

    Treatment adherence measured by changes in nutritional compliance (self-reported). Unit of measure: Description of diet (qualitative data).

  4. Treatment adherence 3

    Time frame: Day 150 to Day 365

    Treatment adherence measured by discontinuation (and reasons behind it). Unit of measure: Incidence of discontinuation with categorized reasons.

Secondary outcomes

  1. Emotional outcome 1

    Time frame: Baseline (Day 1) to Day 365

    These tend to be sensitive to change in short-term and will include distress assessed by the Depression Anxiety and Stress Scale (DASS-21) and the distress thermometer. Minimum Value: 0. Maximum Value: 63. Interpretation: Higher scores indicate worse outcomes (greater levels of depression, anxiety, and stress).

  2. Emotional outcome 2

    Time frame: Baseline (Day 1) to Day 365

    These tend to be sensitive to change in short-term and will include Weight Self-Stigma Questionnaire (S-WSSQ). Minimum Value: 12. Maximum Value: 60. Interpretation: Higher scores indicate worse outcomes (greater self-stigma related to weight).

  3. Emotional outcome 3

    Time frame: Baseline (Day 1) to Day 365

    These tend to be sensitive to change in short-term and will include perceived self-efficacy assessment by the General Self-Efficacy Scale (GSE). Minimum Value: 10. Maximum Value: 40. Interpretation: Higher scores indicate better outcomes (greater self-efficacy).

  4. Health-related Quality of Life (HrQoL)

    Time frame: Baseline (Day 1) to Day 365

    Quality of life tends to change over longer periods of time, and often do require follow-ups of 6 months or one year. However, some dimensions (e.g. mental) are estimated to change faster in shorter periods. HrQoL will be assessed with regard to the children by the caregivers' perspective from the KIDSCREEN-10. Minimum Value: 10. Maximum Value: 50. Interpretation: Higher scores indicate better outcomes (better health-related quality of life).

  5. Levels of physical activity

    Time frame: Baseline (Day 1) to Day 365

    Life-style questionnaires on Levels of physical activity (APALQ; Assessment of Physical Activity Levels Questionnaire ). Minimum Value: Varies based on questionnaire design. Maximum Value: Varies based on questionnaire design. Interpretation: Higher scores generally indicate better outcomes (higher levels of physical activity).

  6. Height

    Time frame: Baseline (Day 1) to Day 365

    From bioimpedance scale. Standard medical measurement. Unit of measure: meters.

  7. Weight

    Time frame: Baseline (Day 1) to Day 365

    From bioimpedance scale. Standard medical measurement. Unit of measure: kilograms.

  8. Body Mass Index (BMI)

    Time frame: Baseline (Day 1) to Day 365

    From bioimpedance scale. Calculated from height and weight. Unit of measure: kg/m²

  9. Blood pressure

    Time frame: Baseline (Day 1) to Day 365

    Standard pressure measurement. Unit of measure: mmHg.

  10. Time since diagnosis

    Time frame: Baseline (Day 1) to Day 365

    From patient medical records or self-reported data. Unit of measure: weeks, months or years.

  11. Previous obesity treatments

    Time frame: Baseline (Day 1) to Day 365

    From patient medical records and self-reported data. Unit of measure: Description of treatment (qualitative data).

  12. Cholesterol levels

    Time frame: Baseline (Day 1) to Day 365

    Blood test results. Unit of measure: mg/dL

  13. Complications

    Time frame: Baseline (Day 1) to Day 365

    From patient medical records or self-reported. Unit of measure: Incidence and type of complications (qualitative data)

  14. Step count

    Time frame: Baseline (Day 1) to Day 396

    From wearable device. Unit of measure: number of steps per day.

  15. Physical activity levels

    Time frame: Baseline (Day 1) to Day 300

    From wearable device. Unit of measure: minutes of moderate to vigorous activity per day.

  16. Sleep quality

    Time frame: Baseline (Day 1) to Day 300

    From wearable device. Unit of measure: Sleep score or duration and quality of sleep (hours and sleep stages).

  17. Heart rate

    Time frame: Baseline (Day 1) to Day 300

    From wearable device. Unit of measure: average resting heart rate (beats per minute).

  18. 6-minute walk test performance

    Time frame: Baseline (Day 1) to Day 365

    Standardized 6-minute walk test. Unit of measure: distance covered in meters.

  19. System Usability

    Time frame: Day 150 to 300

    Measures the perceived usability of ACDP. Minimum Value: 0. Maximum Value: 10. Interpretation: Higher scores indicate better perceibed usability

Sponsors and collaborators

Lead sponsor

Adhera Health, Inc.

Industry

Collaborators

  • Hospital Universitario Miguel Servet, Zaragoza
  • University of Seville
  • University of Valencia

Registry information

Acronym: DALIA

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 25, 2024
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.